Insight Molecular Diagnostics Inc. Common Stock IMDX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$4.29M+81.3% | -$22.96M-111% | -$10.85M-11.4% | -$9.74M-46.0% | -$6.67M+80.1% | ||
| $631K+12.1% | $563K-3.6% | $584K+4.5% | $559K+15.5% | $484K-10.5% | ||
| $615K-14.7% | $721K+38.4% | $521K+3.4% | $504K+6.6% | $473K-5.2% | ||
| -$971K— | —— | -$254K+91.6% | -$3.03M-257% | $1.93M+37.3% | ||
| -$64K— | —— | —— | $234K+378% | $49K-72.5% | ||
| -$105K-103% | $3.56M+202% | $1.18M+138% | -$3.11M-403% | $1.03M+45.9% | ||
| -$449K-540% | $102K— | —— | $104K+22.4% | $85K+10.4% | ||
| $0-100% | $14.59M— | $0— | $0-100% | $7K-100.0% | ||
| -$83K-315% | -$20K+64.9% | -$57K-62.9% | -$35K-16.7% | -$30K+82.1% | ||
| -$5.92M— | —— | $3.38M+20.5% | $2.8M+219% | $879K+106% | ||
| -$7.64M-37.8% | -$5.55M-23.2% | -$4.5M+28.5% | -$6.3M-7.9% | -$5.84M-9.1% | ||
| $613K-58.6% | $1.48M+40.9% | $1.05M+201% | $349K+13.7% | $307K+43.5% | ||
| -$613K+58.6% | -$1.48M-40.9% | -$1.05M-201% | -$349K-13.7% | -$307K-46.2% | ||
| $26.02M— | —— | —— | —— | $29.14M+186% | ||
| —— | $18K0.0% | $18K0.0% | $18K0.0% | $18K— | ||
| —— | $5000.0% | $5000.0% | $5000.0% | $500— | ||
| $24.7M— | —— | —— | —— | $28.56M+164% | ||
| -$10K+33.3% | -$15K— | —— | —— | -$19K-533% | ||
| $16.44M— | —— | —— | —— | $22.39M— | ||
| $19K-13.6% | $22K-8.3% | $24K+14.3% | $21K-12.5% | $24K-4.0% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $0— | $0— | $0— | $0-100% | $7K-68.2% | ||
| -$5.92M— | —— | $3.38M+20.5% | $2.8M+219% | $879K+106% | ||
| $32K-15.8% | $38K0.0% | $38K-48.6% | $74K+429% | $14K-72.0% | ||
| $5K+133% | -$15K— | —— | —— | -$39K-218% | ||
| -$83K-315% | -$20K+64.9% | -$57K-62.9% | -$35K-16.7% | -$30K+82.1% | ||
| -$449K-540% | $102K— | —— | $104K+22.4% | $85K+10.4% | ||
| $1.18M— | —— | —— | —— | $487K-41.7% | ||
| $143K-19.7% | $178K+48.3% | $120K+5.3% | $114K+16.3% | $98K+19.5% | ||
| -$10K+33.3% | -$15K— | —— | —— | -$19K-533% | ||
| $196K— | —— | —— | —— | $0— | ||
| -$83K-315% | -$20K+64.9% | -$57K-62.9% | -$35K-16.7% | -$30K+82.1% | ||
| $0-100% | $765K+673% | $99K-46.5% | $185K+108% | $89K— | ||
| $485K-62.1% | $1.28M— | —— | —— | $1.07M+297% | ||
| —— | $5000.0% | $5000.0% | $5000.0% | $500— | ||
| $0— | $0— | $0— | $0— | $0— | ||
| -$8.25M-17.5% | -$7.02M-26.5% | -$5.55M+16.5% | -$6.65M-8.2% | -$6.15M-10.4% | ||
| -$8.25M-17.5% | -$7.02M-26.5% | -$5.55M+16.5% | -$6.65M-8.2% | -$6.15M-10.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Insight Molecular Diagnostics Inc. Common Stock generate?
- Insight Molecular Diagnostics Inc. Common Stock (IMDX) generated -$24.0M in operating cash flow over the trailing twelve months.
- What is Insight Molecular Diagnostics Inc. Common Stock's free cash flow?
- After $3.5M of capital expenditures, Insight Molecular Diagnostics Inc. Common Stock's free cash flow was -$27.5M over the trailing twelve months, down 16.9% year over year.
- Where does Insight Molecular Diagnostics Inc. Common Stock's cash flow data come from?
- Every line is extracted from Insight Molecular Diagnostics Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
